No clinically documented drug interactions with GHK-Cu or BPC-157 have been established in the available literature
A 2003 prospective cohort study by Khavinson and Morozov found that epithalon had the following effects when administered to a sample of 266 adults over the age of 60 [9]: Decreased incidence of ischemic heart disease Decreased incidence of hypertension disease Lowered rates of deforming osteoarthritis and osteoporosis More recently, a 2020 study by Khavinson et al
Put the three together and the pitch is a loop: supply NAD+, protect NAD+, then flip on the pathways that spend it productively
Started with Bpc-157 at 0.25 mg daily near my shoulder plus Tb-500 at 2.5 mg twice weekly
Controlled-release options include but are not limited to liposomes, cyclodextrins, biodegradable polymers, dispersible polymers, emulsions, microspheres or microparticles, other viscous media, paints, foams, in spongy materials, liposomes, nanocapsules or nanospheres, and combinations thereof
